Switching to biosimilar
16 May, 2017 | 20:01h | UTCSwitching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial – The Lancet (link to abstract – $ for full-text)
Commentary: Celltrion Healthcare: Lancet Publishes Full Data-Set from Influential NOR-SWITCH Study – Business Wire (free)